{
    "Trade/Device Name(s)": [
        "CellSearch\u2122 Circulating Tumor Cell Kit",
        "CellSearch\u2122M Circulating Tumor Cell Kit (Epithelial)"
    ],
    "Submitter Information": "Veridex, LLC",
    "510(k) Number": "K073338",
    "Predicate Device Reference 510(k) Number(s)": [
        "K071729"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NQI"
    ],
    "Summary Letter Date": "February 26, 2008",
    "Summary Letter Received Date": "November 28, 2007",
    "Submission Date": "November 27, 2007",
    "Regulation Number(s)": [
        "21 CFR 866.6020"
    ],
    "Regulation Name(s)": [
        "Immunomagnetic Circulating Cancer Cell Selection and Enumeration System"
    ],
    "Analyte Class(es)": [
        "cancer molecular",
        "immunology"
    ],
    "Analyte(s)": [
        "Circulating tumor cells (CTC) of epithelial origin (CD45-, EpCAM+, cytokeratins 8, 18+, and/or 19+)"
    ],
    "Specimen Type(s)": [
        "Whole blood"
    ],
    "Specimen Container(s)": [
        "CellSave Preservative Tube"
    ],
    "Instrument(s)/Platform(s)": [
        "CellTracks\u00ae AutoPrep\u00ae System",
        "CellTracks\u00ae Analyzer II",
        "CellSpotter\u00ae Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Immunomagnetic capture",
        "Fluorescent immunostaining"
    ],
    "Methodologies": [
        "Cell selection and enumeration",
        "Immunomagnetic separation",
        "Immunofluorescence"
    ],
    "Submission Type(s)": [
        "Kit",
        "System",
        "Reagent",
        "Analyzer",
        "Control",
        "Specimen collection device"
    ],
    "Document Summary": "FDA 510(k) summary for CellSearch Circulating Tumor Cell Kit for enumeration of CTCs of epithelial origin in whole blood to monitor metastatic breast, colorectal, or prostate cancer.",
    "Indications for Use Summary": "Intended for the enumeration of circulating tumor cells (CTC) of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+) in whole blood to aid in monitoring patients with metastatic breast, colorectal, or prostate cancer; to be used in conjunction with other clinical assessment methods.",
    "fda_folder": "Immunology"
}